Wednesday, November 29 2023 | 08 h 21 min | Vision Science
A new company, Beacon Therapeutics, has launched with a focus on gene therapies for cone-rod dystrophy and X-linked retinitis pigmentosa. Beacon will undertake preclinical work on a potential gene therapy for cone-rod dystrophy caused by mutations in the CDHR1 gene.
This work was originally started by Dr. Robert MacLaren (University of Oxford) who is a co-founder and adviser to the company. If these studies are successful, Beacon hopes to move the CDHR1 gene therapy to a human clinical trial in the coming years.